Citations

Showing 10 of 108152 citations.

Dosimetric advantages of proton beam therapy compared to intensity-modulated radiation therapy for retroperitoneal chordoma
Yu, Nathan Y. , Vora, Sujay A., Yu, Nathan

Mayo Clinic

Rare Tumors | September 23, 2019 | Volume: 11 | Issue: No issue available | Pages: No page available

10.1177/2036361319878518 | PMID 31579112 Get It

Retroperitoneal chordomas are exceedingly rare and account for less than 5% of all primary bone malignancies. Their etiology remains unknown. We report a rare case of an extravertebral chordoma of the retroperitoneum in a 71-year-old man treated with surgical resection and post-operative spot-scanning proton beam therapy. We describe how to safely treat a retroperitoneal target to a prescription dose over 70 Gy (relative biological effectiveness) with spot-scanning proton beam therapy and also report a dosimetric comparison of spot-scanning proton beam therapy versus intensity-modulated radiation therapy. This case not only highlights a rare diagnosis of an extravertebral retroperitoneal chordoma but it also draws attention to the dosimetric advantages of proton beam therapy and illustrates a promising radiotherapeutic option for retroperitoneal targets.
Proposed new diagnostic criteria for chronic migraine
Chalmer, Mona Ameri , Hansen, Thomas Folkmann , Lebedeva, Elena R. , Dodick, David W. , Lipton, Richard B. , Olesen, Jes

Mayo Clinic

Cephalalgia | September 23, 2019 | Volume: 40 | Issue: 4 | Pages: 399-406

10.1177/0333102419877171 | PMID 31544467 Get It

Introduction ICHD-3 criteria for chronic migraine (CM) include a mixture of migraine and tension-type-like headaches and do not account for patients who have a high frequency of migraine but no other headaches. Materials and methods Patients from the Danish Headache Center and their relatives with ICHD-3 defined CM were compared with patients with high frequency episodic migraine (HFEM). Danish registries were used to compare the socioeconomic impact in these two groups. A Russian student population was used to determine the generalizability of the number of patients fulfilling CM and the proposed diagnostic criteria for CM. Results There was no difference in the demographic profile between the two groups in the Danish cohort. The number of lifelong or annual attacks ( p > 0.3), comorbid diseases, or self-reported effect of triptans ( p = 1) did not differ. HFEM patients purchased more triptans than CM patients ( p = 0.01). CM patients received more early pension ( p = 0.00135) but did not differ from HFEM patients with regard to sickness benefit ( p = 0.207), cash assistance ( p = 0.139), or rehabilitation benefit ( p = 1). Discussion Patients with HFEM are comparable to CM patients with regard to chronicity and disability. We therefore suggest classifying CM as ≥ 8 migraine days per month (proposed CM), disregarding the need for ≥ 15 headache days per month. The proposed diagnostic criteria for CM approximately doubled the number of patients with CM in both the Danish and the Russian materials. Extending the definition of CM to include patients with HFEM will ensure that patients with significant disease burden and unmet treatment needs are identified and provided appropriate access to the range of treatment options and resources available to those with CM. Conclusion Patients with migraine on eight or more days but not 15 days with headache a month are as disabled as patients with ICHD-3 defined CM. They should be included in revised diagnostic criteria for chronic migraine.
Incidence of Thoracic Outlet Syndrome in Patients With Postural Orthostatic Tachycardia Syndrome
Kumar, Arathi Prabha, Ang, C, Rishitha, Bandi Naga, Kumar, V. Krishna, Suleman, Amer

Mayo Clinic

Journal for Vascular Ultrasound | September 23, 2019 | Volume: 43 | Issue: 4 | Pages: 171-176

10.1177/1544316719872365 Get It

Thoracic outlet syndrome (TOS) refers to a constellation of symptoms resulting from neurovascular compression at the thoracic outlet, causing some combination of pain in the neck and upper extremity, weakness, sensory loss, paresthesia, swelling, and discoloration. Classification of TOS would depend on the anatomical structure that is compressed: venous TOS (VTOS)—compression of Subclavian vein; arterial TOS (ATOS)—compression of subclavian artery; and neurogenic TOS (NTOS)—compression of brachial plexus. Postural Orthostatic Tachycardia Syndrome (POTS) is characterized by orthostatic tachycardia that develops in the absence of orthostatic hypotension, with a symptom duration of >6 months. POTS is now known to be commonly associated with Ehlers-Danlos Syndrome (EDS), thereby raising speculation about the extent of prevalence of TOS symptoms in EDS patients. The aim of the study was to quantify the influx of patients with POTS, reporting symptoms of arm fatigue with or without numbness and tingling. The symptoms were quantified initially by conducting postural maneuvers that would reproduce the symptoms, to rule-in the possibility of TOS and further confirmed by using ultrasonography in upper limbs as the imaging modality of choice to evaluate arterial and/or venous compression. This study also looks at the presence of a concurrent diagnosis of EDS among the symptomatic patients who test positive for TOS.
The Miami International Evidence-based Guidelines on Minimally Invasive Pancreas Resection
Asbun, Horacio J. , Moekotte, Alma , Vissers, Frederique L., Kunzler, F. , Cipriani, Federica , D’Angelica, Michael I. , Balduzzi, Alberto , Bassi, Claudio , Björnsson, Bergþór , Boggi, Ugo , Callery, Mark P., Chiaro, Marco Del , Coimbra, Felipe José Fernández , Conrad, Claudius , Cook, Andrew , Coppola, Alessandro , Dervenis, Christos, Dokmak, Safi , Edil, Barish H. , Giulianotti, Pier Cristoforo , Hansen, Paul D., Heijde, Nicky van der , Hilst, Jony van , Hester, Caitlin A. , Hogg, Melissa E. , Jarufe, Nicolás , Jeyarajah, D. Rohan, Kim, Song Cheol, Khatkov, Igor , Kokudo, Norihiro , Kooby, David A. , Korrel, Maarten , Leon, Francisco J. de, Lluís, Núria , Lof, Sanne , Demartines, Nicolas , Merchant, Nipun B. , Molenaar, I. Quintus, Moravek, Cassadie, Mou, Yiping , Nealon, William H. , Palanivelu, Chinnusamy, Pessaux, Patrick , Pitt, Henry A. , Primrose, John N., Rawashdeh, Arab , Sanford, Dominic E. , Senthilnathan, Palanisamy, Shrikhande, Shailesh V. , Stauffer, John , Takaori, Kyoichi , Tang, Chung Ngai, Vollmer, Charles M., Wakabayashi, Go , Walsh, R. Matthew , Wang, Shin-E, Zinner, Michael J. , Wolfgang, Christopher L. , Zureikat, Amer H. , Zwart, M. , Conlon, Kevin C. , Kendrick, Michael L., Zeh, Herbert J. , Hilal, Mohammad Abu, Besselink, Marc G. , Primrose, John , Hilal, Mohammad Abu , Demartines, N , A Stauffer, John , Alseidi, Adnan A. , Edwin, Bjørn , Han, Ho-Seong , Jeyarajah, D. Rohan , Keck, Tobias , Machado, Marcel Autran C. , Martinie, John B. , Moravek, Cassadie, Nakamura, Masafumi , Palanivelu, Chinnusamy , Polanco, Patricio Marcelo , Talamonti, Marina , Wang, Shin‐E , Kendrick, Michael L. , Besselink, Marc G , Cipriani, Federica

Mayo Clinic

Annals of Surgery | September 22, 2019 | Volume: 271 | Issue: 1 | Pages: 1-14

10.1097/sla.0000000000003590 | PMID 31567509 Get It

Objective: The aim of this study was to develop and externally validate the first evidence-based guidelines on minimally invasive pancreas resection (MIPR) before and during the International Evidence-based Guidelines on Minimally Invasive Pancreas Resection (IG-MIPR) meeting in Miami (March 2019). Summary Background Data: MIPR has seen rapid development in the past decade. Promising outcomes have been reported by early adopters from high-volume centers. Subsequently, multicenter series as well as randomized controlled trials were reported; however, guidelines for clinical practice were lacking. Methods: The Scottisch Intercollegiate Guidelines Network (SIGN) methodology was used, incorporating these 4 items: systematic reviews using PubMed, Embase, and Cochrane databases to answer clinical questions, whenever possible in PICO style, the GRADE approach for assessment of the quality of evidence, the Delphi method for establishing consensus on the developed recommendations, and the AGREE-II instrument for the assessment of guideline quality and external validation. The current guidelines are cosponsored by the International Hepato-Pancreato-Biliary Association, the Americas Hepato-Pancreato-Biliary Association, the Asian-Pacific Hepato-Pancreato-Biliary Association, the European-African Hepato-Pancreato-Biliary Association, the European Association for Endoscopic Surgery, Pancreas Club, the Society of American Gastrointestinal and Endoscopic Surgery, the Society for Surgery of the Alimentary Tract, and the Society of Surgical Oncology. Results: After screening 16,069 titles, 694 studies were reviewed, and 291 were included. The final 28 recommendations covered 6 topics; laparoscopic and robotic distal pancreatectomy, central pancreatectomy, pancreatoduodenectomy, as well as patient selection, training, learning curve, and minimal annual center volume required to obtain optimal outcomes and patient safety. Conclusion: The IG-MIPR using SIGN methodology give guidance to surgeons, hospital administrators, patients, and medical societies on the use and outcome of MIPR as well as the approach to be taken regarding this challenging type of surgery.
Cutaneous Eruption Heralding Squamous Cell Carcinoma of the Lung: Answer
Montagnon, Carmen M. , Tolkachjov, Stanislav N. , Pittelkow, Mark R. , Bridges, Alina G.

Mayo Clinic

The American Journal of Dermatopathology | September 22, 2019 | Volume: 41 | Issue: 10 | Pages: 773-774

10.1097/dad.0000000000001189 | PMID 31567297 Get It

Undiagnosed Systemic Mastocytosis Presenting as Postoperative Distributive Shock: A Case Report
Ripoll, Juan G. , Ritter, Matthew J. , Comfere, Thomas B., Gilkey, George D., Smith, Mark M. , Schaff, Hartzell V. , Warner, Matthew A.

Mayo Clinic

A&A Practice | September 22, 2019 | Volume: 13 | Issue: 10 | Pages: 392-395

10.1213/xaa.0000000000001093 | PMID 31567270 Get It

Systemic mastocytosis (SM) is a rare clinical condition resulting from a clonal proliferation of abnormal mast cells. The clinical presentation may vary from mild cutaneous manifestations to aggressive systemic symptoms including intermittent episodes of anaphylaxis. We present a case of a 69-year-old male with abrupt and recurrent episodes of anaphylaxis with refractory distributive shock following cardiac surgery with cardiopulmonary bypass. Following a complex postoperative course, a bone marrow biopsy ultimately confirmed the diagnosis. Although rare, SM should be considered in the differential diagnosis of postoperative patients with unexplained and recurrent episodes of distributive shock.
Treatment of latent TB Infection and the risk of tuberculosis after solid organ transplantation: Comprehensive review
Abad, Cybéle Lara R. , Deziel, Paul J. , Razonable, Raymund R. , Razonable, Raymund R

Mayo Clinic

Transplant Infectious Disease | September 21, 2019 | Volume: 21 | Issue: 6 | Pages: No page available

10.1111/tid.13178 | PMID 31541575 Get It

Abstract Background Mycobacterium tuberculosis disease may occur after treatment of latent TB infection (LTBI). Prompted by a case of reactivation TB disease in a solid organ transplant (SOT) recipient who received LTBI treatment, we reviewed the literature to examine outcomes, adverse effects, resistance, and treatment choices of tuberculosis after LTBI therapy. Methods MEDLINE and Web of Science from inception to 5/2019 were reviewed using key words “latent tuberculosis infection” and “SOT” or “transplantation.” The search yielded nine cases, 41 cohort studies and six randomized controlled trials (RCT). Results Cohort and RCT demonstrated significant reduction in TB disease among transplanted patients who received LTBI therapy; only 56/2651 (2.1%) SOT patients developed TB after LTBI therapy. Adverse drug reactions occurred in 149/1148 (12.9%) and 73/641 (11.4%) of cohort and RCT patients, respectively. Among liver recipients, 56/266 (21%) developed side effects, of which half (29/56, 51.8%) was INH‐related. There was no reported INH resistance. Conclusions Latent TB infection treatment is efficacious in SOT recipients at risk of TB disease. However, tuberculosis may still occur despite LTBI treatment. Hepatotoxicity associated with LTBI therapy is infrequent, although more commonly observed among liver recipients.
Human Pegivirus Infection and Lymphoma Risk: A Systematic Review and Meta-analysis
Link, Brian K. , Call, Timothy G. , Ansell, Stephen M. , Liebow, Mark , Xiang, Jinhua , Nowakowski, Grzegorz S. , Famà, Angelo , Link, Brian K , Larson, Melissa C. , Habermann, Thomas M. , Feldman, Andrew L. , Maurer, Matthew J. , Slager, Susan L. , Stapleton, Jack T. , Cerhan, James R.

Mayo Clinic

Clinical Infectious Diseases | September 20, 2019 | Volume: 71 | Issue: 5 | Pages: 1221-1228

10.1093/cid/ciz940 | PMID 31671178 Get It

AbstractBackgroundHuman pegivirus (HPgV) is a single-strand RNA virus belonging to the Flaviviridae. Although no definitive association between HPgV infection and disease has been identified, previous studies have suggested an association of HPgV viremia with risk of lymphomas.MethodsWe conducted a systematic review and meta-analysis, including 1 cohort study and 14 case-control studies, assessing the association of HPgV viremia with adult lymphomas. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using a random-effects model, overall and by geographic region and lymphoma subtype.ResultsThe overall OR for lymphoma was 2.85 (95% CI, 1.98–4.11), with statistically significantly elevated ORs observed in 8 of 15 studies. There was a small amount of heterogeneity among studies (I2 = 28.9%; Q = 18.27, P = .16), and the funnel plot provided no evidence for publication bias. The strongest association with lymphoma risk was observed for studies from Southern Europe (OR, 5.68 [95% CI, 1.98–16.3]), whereas weaker ORs (with 95% CIs) were observed for studies from North America (2.24 [1.76–2.85]), Northern Europe (2.90 [.45–18.7), and the Middle East (2.51 [.87–7.27]), but all of similar magnitude. Participants with HPgV viremia had statistically significantly increased risks (OR [95% CI]) for developing diffuse large B-cell (3.29 [1.63–6.62]), follicular (3.01 [1.95–4.63]), marginal zone (1.90 [1.13–3.18]), and T-cell (2.11 [1.17–3.89]) lymphomas, while the risk for Hodgkin lymphoma (3.53 [.48–25.9]) and chronic lymphocytic leukemia (1.45 [.45–4.66]) were increased but did not achieve statistical significance.ConclusionsThis meta-analysis supports a positive association of HPgV viremia with lymphoma risk, overall and for the major lymphoma subtypes.
Intraoperative Events in Liver Transplantation Using Donation After Circulatory Death Donors
Chadha, Ryan , Croome, Kristopher P. , Aniskevich, Stephen , Pai, Sher‐Lu , Nguyen, Justin H. , Burns, Justin M. , Perry, Dana K. , Chadha, Ryan , Nguyen, Justin, Burns, Justin, Perry, Dana, Taner, C. Burcin , Croome, Kris P , Pai, Sher-Lu , Aniskevich, Stephen

Mayo Clinic

Liver Transplantation | September 20, 2019 | Volume: 25 | Issue: 12 | Pages: 1833-1840

10.1002/lt.25643 | PMID 31539458 Get It

Liver grafts from donation after circulatory death (DCD) are a source of organs to decrease wait‐list mortality. While there have been lower rates of graft loss, there are concerns of an increased incidence of intraoperative events in recipients of DCD grafts. We aim to look at the incidence of intraoperative events between recipients of livers from DCD and donation after brain death (DBD) donors. We collected data for 235 DCD liver recipients between 2006 and 2017. We performed a 1:1 propensity match between these patients and patients with DBD donors. Variables included recipient age, liver disease etiology, biological Model for End‐Stage Liver Disease (MELD) score, allocation MELD score, diagnosis of hepatocellular carcinoma, and year of transplantation. DCD and DBD groups had no significant differences in incidence of postreperfusion syndrome (P = 0.75), arrhythmia requiring cardiopulmonary resuscitation (P = 0.66), and treatments for hyperkalemia (P = 0.84). In the DCD group, there was a significant increase in amount of total intraoperative and postreperfusion blood products (with exception of postreperfusion packed red blood cells) utilized (P < 0.05 for all products), significant differences in postreperfusion thromboelastography parameters, as well as inotropes and vasopressors used (P < 0.05 for all infusions). There was no difference in patient (P = 0.49) and graft survival (P = 0.10) at 1, 3, and 5 years. In conclusion, DCD grafts compared with a cohort of DBD grafts have a similar low incidence of major intraoperative events, but increased incidence of transient vasopressor/inotropic usage and increased blood transfusion requirements. This does not result in differences in longterm outcomes. While centers should continue to look at DCD liver donors, they should be cognizant regarding intraoperative care to prevent adverse outcomes.
Adaptation and Validation of a Spanish version of the Treatment Burden Questionnaire in Patients with Multiple Sclerosis
Fiol, Marcela , Peña, Fernando Vázquez , Vanotti, Sandra, Ysrraelit, María Célica , Terrasa, Sergio , Tran, Viet-Thi , Montori, Víctor M. , Correale, Jorge Daniel

Mayo Clinic

No container title available | September 20, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.2.10092/v2 Get It

Abstract Background: The Treatment Burden Questionnaire (TBQ) is a self-reported measure of the effect of treatment workload on patient wellbeing. We sought to validate the TBQ in Spanish and use it to estimate the burden of treatment in Argentinian patients with multiple sclerosis (MS). Methods: The TBQ was forward-backward translated into Spanish. Two focus groups and 25 semi-structured interviews focused on wording and possible item exclusion. Validation was performed in 2 steps. First, 162 patients across a range of MS severity completed the questionnaire. Confirmatory factor analysis assessed the dimensional structure of the TBQ. Construct validity was assessed by studying correlations with fatigue and quality of life (QoL). Then, in a second cohort of 171 patients, we evaluated the association between TBQ scores and patients’ sex, age, education level, employment status, type of MS, disease duration, comorbidities, EDSS, pharmacological treatment and medication adherence. Results: The questionnaire presented a 3-factor structure in which burden was related to pharmacological treatment; comprehensive health assistance; and psycho-social-economic context. Composite reliability was > 0.8 for all factors. TBQ showed positive correlation with fatigue (rs= 0.467, p=0.006), negative correlation with QoL (rs -0.446, p=0.009). For the second cohort, total TBQ score was 43 (SD 29). Lowest scores were observed on self-monitoring (0.53, SD 1.3) and highest for administrative load (4.2, SD 3.4). Inverse association was found between the TBQ score and medication adherence (r 0.243 p=0.001). TBQ scores also correlated with daily patient pill/injection requirements (r 0.175 p=0.020). Individuals receiving injectable treatment scored higher than patients on oral drugs (total TBQ 51 (SD 32) vs 39 (SD 27) p=0.002). Conclusions: The TBQ in Spanish is a reliable instrument and showed adequate correlation with QoL and adherence scales in MS patients. TBQ may benefit health resources allocation and provide tailor therapeutic interventions to construct a minimally disruptive care.